Showing 5921-5930 of 9807 results for "".
- US FDA Approves Saphnelo for Lupushttps://practicaldermatology.com/news/us-fda-approves-saphnelo-for-lupus/2460876/The U.S. Food and Drug Administration (FDA) approved Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. Developed by AstraZeneca, Saphnelo is a monoclonal antibody administered by intravenous (IV)
- Dr. James Q. Del Rosso Named Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/dr-james-q-del-rosso-named-senior-vice-president-of-clinical-research-and-strategic-development-at-advanced-dermatology-and-cosmetic-surgery/2460873/James Q. Del Rosso, DO is now Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgery (ADCS). Dr. James Del Rosso and Ms. Allison Lynch, Chief Operating Officer of Pathology and Research Divisions, will oversee the company’
- Survey: Cleansing Habits of Americans Are Not Up to Dermatologist Standardshttps://practicaldermatology.com/news/survey-cleansing-habits-of-americans-are-not-up-to-dermatologist-standards/2460871/Fully 91 percent of consumers agree that cleansing is important, only 23 percent say that a dermatologist would be pleased with their facial cleansing habits, according to a new survey conducted by CeraVe of 2,000 U.S. adults aged 18-40. This is why this CeraVe is helping
- LiVDerm Brings SBS Part II to Hollywood, FL this Fallhttps://practicaldermatology.com/news/livderm-brings-sbs-part-ii-to-hollywood-fl-this-fall/2460868/SBS Part II: The Aesthetic Dermatology Summit comes to Hollywood, FL, September 23-25, closing out the two-part 19th Annual South Beach Symposium. Produced by LiVDerm, the event is centered on the latest and most re
- PASI-HD: Modification to PsO Severity Scale Aims at Mild-to-Moderate Diseasehttps://practicaldermatology.com/news/pasi-hd-modification-to-pso-severity-scale-aims-at-mild-to-moderate-disease/2460867/A new modification to the Psoriasis Area and Severity Index (PASI) aims to address limitations of the scale when used to assess mild-to-moderate disease. PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less
- Rhode Island Takes Steps to Increase Sunscreen Access for Childrenhttps://practicaldermatology.com/news/rhode-island-takes-steps-to-increase-sunscreen-access-for-children/2460866/Rhode Island students will now be able to possess and utilize sunscreen at school and school-related activities, thanks to advocacy from the American Society for Dermatologic Surgery Association (ASDSA) and the Rhode Island Dermatology Society. Governor Daniel McKee signed into la
- Sunscreen Recall: J & J Pulls Five Sunscreens Due to Benzene Contaminationhttps://practicaldermatology.com/news/sunscreen-recall-j-j-pulls-five-sunscreens-due-to-benzene-contamination/2460865/Johnson & Johnson is recalling five Neutrogena and Aveeno aerosol sunscreens after finding low levels of benzene in some samples. The recalled sunscreen products include: AVEENO PROTECT + REFRESH aerosol sunscreen NEUTROGENA Beach Def
- News You Can Use: Hydrafacial Offers Monthly Scholarships for Connect Certification Programhttps://practicaldermatology.com/news/news-you-can-use-hydrafacial-offers-monthly-scholarships-for-connect-certification-program/2460863/HydraFacial is now offering a scholarships for their Connect certification program The Connect certification program comprises business building, marketing, cross-selling, social media, networking, mentoring, and leadership in a 3-level program that includes video assessments
- Country Singer Jessie James Decker Joins Forces with Geneo to Promote Skincarehttps://practicaldermatology.com/news/country-singer-jessie-james-decker-joins-forces-with-geneo-to-promote-skincare/2460861/Geneo is partnering with country singer Jessie James Decker to promote the importance of skincare and self-care. Geneo is a three-in-one fully customizable facial treatment platform. "I've never been one to get facials in the past but I have noticed ove
- Arcutis Enrolls First Patient in Phase 3 Trial of Roflumilast for SDhttps://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-3-trial-of-roflumilast-for-sd/2460860/The first patient has been enrolled in the pivotal Phase 3 clinical trial evaluating topical roflumilast foam (ARQ-154) as a potential treatment for seborrheic dermatitis. Arcutis Biotherapeutics, Inc. is develo